Loading…
Loading…
MEDIF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MEDIF and 80,000+ other tickers.
See exactly how MEDIF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MEDIF and 80,000+ other tickers.
MediPharm Labs Corp. operates as a pharmaceutical firm specializing in the manufacturing and distribution of pharmaceutical-grade cannabis oils, concentrates, and advanced derivative products. The company's market presence spans Canada, Australia, Germany, and other international territories. Its comprehensive services encompass the formulation, processing, packaging, and distribution of sophisticated cannabinoid-based offerings. Additionally, MediPharm Labs provides GMP-compliant sourcing, packaging, and distribution services for cannabis flower. The organization was established in 2015 and is headquartered in Barrie, Canada.
MediPharm Labs Corp. (LABS:CA) Q2 2026 Earnings Call Transcript
Q2 2026 Adjusted EBITDA1 of $0.9M, the Company's strongest quarterly performance since 20192 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 versus Q2 2025 Net Revenue of $10.0M, an increase of 11% versus Q1 2026 with German revenue increasing 45% sequentially and 33% year over year Cash of $9.9M consistent with Q1 2026, and the Company remains virtually debt free, with outright ownership of two production facilities appraised at over $15M Positive Phase II LiBBY trial results presented demonstrating statistically significant improvement in agitation symptoms using MediPharm's proprietary cannabinoid formulation Management to Host Conference Call / Webcast on August 13th, 2026, at 10:00 am ET TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2026 ("Q2 2026"). The Company improved sequentially on revenue, gross margin and Adjusted EBITDA versus the three months ended March 31, 2026 ("Q1 2026").
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three and six months ended June 30th, 2026, before markets open on Thursday, August 13th, 2026.
TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life's End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company's proprietary oral cannabinoid formulation for the treatment of agitation in patients with advanced dementia. The results were presented by the LiBBY team at AAIC in London, United Kingdom on July 14, 2026.
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “Meeting”) of holders of common shares (“Shareholders”) held today. There were 389 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 130,357,074 common shares, representing 30.68% of MediPharm's total issued and outstanding common shares as of the record date for the Meeting.